SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed	by a Party other than the Registrant □				
Chec	k the appropriate box:				
	Preliminary Proxy Statement				
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))				
	Definitive Proxy Statement				
X	Definitive Additional Materials				
	Soliciting Material Pursuant to § 240.14a-12				
	Acumen Pharmaceuticals, Inc. (Name of Registrant as Specified In Its Charter)				
	(Name of Person(s) Filing Proxy Statement if other than the Registrant)				
Payment of Filing Fee (Check all boxes that apply):					
X	No fee required.				
	Fee paid previously with preliminary materials				
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11				

Filed by the Registrant \boxtimes



Your vote matters!



Scan QR for digital voting

Important Notice Regarding the

Availability of Proxy Materials

For the Stockholders Meeting To Be Held On June 4, 2024 For Stockholders of record as of April 8, 2024

Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K

To order paper materials, use one of the following methods.



nternet:

www.investorelections.com/ABOS



Call:

1-866-648-8133



Email:

paper@investorelections.com

* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.



Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

Acumen Pharmaceuticals, Inc. Annual Meeting of Stockholders

Tuesday, June 4, 2024 11:00 AM Eastern Time

Annual Meeting to be held live via the internet - please visit www.proxydocs.com/ABOS for more details.

You must register to attend the meeting online and/or participate at www.proxydocs.com/ABOS

To view the proxy materials, VOTE, and obtain directions to attend the meeting, go to www.proxydocs.com/ABOS

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 24, 2024.

SEE REVERSE FOR FULL AGENDA

Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved



Acumen Pharmaceuticals, Inc. Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR EACH OF THE NOMINEES FOR DIRECTOR IN PROPOSAL 1, AND FOR PROPOSAL 2

PROPOSAL

- 1. To elect two Class III directors to the Board of Directors, each to hold office until the 2027 Annual Meeting of Stockholders.
 - 1.01 Daniel O'Connell
 - 1.02 Nathan Fountain, M.D.
- 2. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
- 3. To conduct any other business properly brought before the meeting or any adjournments, continuations, or postponements thereof.